Phosphorylated tau in plasma could be a biomarker of lower motor neuron impairment in amyotrophic lateral sclerosis.

[1]  P. Avoni,et al.  Elevated plasma p-tau181 levels unrelated to Alzheimer’s disease pathology in amyotrophic lateral sclerosis , 2023, Journal of Neurology, Neurosurgery, and Psychiatry.

[2]  S. Messina,et al.  Phenotypic correlates of serum neurofilament light chain levels in amyotrophic lateral sclerosis , 2023, Frontiers in Aging Neuroscience.

[3]  A. Nairn,et al.  Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease , 2022, Alzheimer's Research & Therapy.

[4]  S. Corti,et al.  Correlation between clinical phenotype and electromyographic parameters in amyotrophic lateral sclerosis , 2022, Journal of Neurology.

[5]  J. Trojanowski,et al.  Elevated Plasma Phosphorylated Tau 181 in Amyotrophic Lateral Sclerosis , 2022, Annals of neurology.

[6]  N. Dahodwala,et al.  Reliable and efficient scale to assess upper motor neuron disease burden in amyotrophic lateral sclerosis , 2019, Muscle & nerve.

[7]  T. Hortobágyi,et al.  Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria , 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[8]  F. Madotto,et al.  The validation of the Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS) , 2016, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[9]  A. Al-Chalabi,et al.  A proposed staging system for amyotrophic lateral sclerosis , 2012, Brain : a journal of neurology.

[10]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.